Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Colorectal Neoplasms 240Rectal Neoplasms 93Colonic Neoplasms 91Pancreatic Neoplasms 87Stomach Neoplasms 68Neoplasm Metastasis 47Esophageal Neoplasms 41Neoplasms 36Small Cell Lung Carcinoma 29Lung Neoplasms 29Neuroblastoma 28Glioblastoma 28Glioma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 22Adenocarcinoma Of Esophagus 20Gliosarcoma 19Breast Neoplasms 18Astrocytoma 18Esophageal Squamous Cell Carcinoma 17Central Nervous System Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Oligodendroglioma 13Adenocarcinoma 13Rhabdomyosarcoma 10Gastrointestinal Neoplasms 10Biliary Tract Neoplasms 10Sarcoma 9Gallbladder Neoplasms 9Cholangiocarcinoma 9

Interventions

Cyclophosphamide 117Rituximab 115fludarabine phosphate 79Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 55Whole-Body Irradiation 52Filgrastim 49Tacrolimus 43Cyclosporine 43Radiotherapy 41Busulfan 41Antilymphocyte Serum 38Etoposide 36Melphalan 34Lenalidomide 31Methotrexate 25fludarabine 23Cord Blood Stem Cell Transplantation 22Bortezomib 20Flow Cytometry 19Cytarabine 19Methylprednisolone 18Bendamustine Hydrochloride 18obinutuzumab 17Prednisone 15Granulocyte Colony-Stimulating Factor 15Carmustine 15sargramostim 14orelabrutinib 14Therapeutics 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell, Marginal Zone × Irinotecan × Clear all
NCT00003245 2018-11-15

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00005626 2012-09-25

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡